Bladder Cancer: Current Challenges and Future Directions.
Dobruch J, Oszczudłowski M. · 2021
Read Bladder Cancer: Current Challenges and Future Directions. by Dobruch J, Oszczudłowski M. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8402079.txt.
Introduction
Dobruch and Oszczudłowski review bladder cancer, the most common cancer of the urinary tract. Care for this disease stayed much the same for many years. New findings now open a fresh era in diagnosis and management.
The authors note that deaths have begun to fall where awareness and lower exposure to cancer-causing agents took hold. Surgery through the urethra is being refined toward stricter, higher-quality technique. New drugs serve patients whose tumors no longer respond to BCG therapy. The worth of wide lymph node removal is under test in trials. Work on tumor biology points toward care matched to each patient.
Catalog record
| CREATOR | Dobruch J, Oszczudłowski M. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Bladder Cancer: Current Challenges and Future Directions By Jakub Dobruch, Maciej Oszczudłowski, Giuseppe Lucarelli Published in: Medicina DOI: 10.3390/medicina57080749 ABSTRACT Abstract Bladder cancer (BCa) is the most common malignancy of the urinary tract and one of the most prevalent cancers worldwide. While the clinical approach to BCa has remained largely unchanged for many years, recent discoveries have paved the way to a new era of diagnosis and management of the disease. BCa-specific mortality started to decrease in the regions with a wide range of activities leading to greater social awareness of the risk factors and the decline in carcinogenic exposure. The urologic community refines the role of transurethral surgery towards more rigorous and high-quality techniques. New agents have been approved for patients with BCG failure who faced radical cystectomy so far. Although radical removal of the bladder is the gold standard for muscle invasive cancer management, the extent and clinical value of lymphadenectomy is currently heavily challenged in randomized trials. Furthermore, alternatives to perioperative chemotherapy have arisen to increase the likelihood of complete treatment delivery and successful oncological outcomes. Finally, improvements in molecular biology and our understanding of tumorigenesis open the era of personalized medicine in bladder cancer. In the present review, the status and future directions in bladder cancer epidemiology, diagnosis and management are thoroughly discussed. Keywords: urinary bladder cancer, surgical treatment, BCG failure, perioperative chemotherapy 1. INTRODUCTION Bladder cancer (BCa) remains the most common malignancy of the urinary tract. In 2018, BCa was diagnosed in 549,393 patients and 199,922 succumbed to the disease worldwide [1]. Although age-standardized incidence (ASIR) shows great diversity among different geographical regions, it is projected to continue the rise within the next decade [2]. A number of BCa risk factors were identified. Apart from geography and age, the risk varies between genders and is heavily influenced by exposure to a number of carcinogens, with cigarette smoking being the most prevalent one [1]. Age-standardized mortality rates (ASMR) started to decline in well-developed countries, while it tends to increase in low-income parts of the globe [3]. The most significant symptom of BCa is either microscopic or gross hematuria. If the bladder tumor is identified, in 75% of cases, urothelial bladder cancer (UBC) confined to the mucosa (NMIBCa—non-muscle invasive disease) is diagnosed [4]. In the remaining 25–30% of patients, BCa has already invaded deeper layers of the bladder wall (MIBCa—muscle-invasive disease) or formed metastases. Transurethral resection of the bladder tumor (TURBT) is the mainstay therapy of those with NMIBCa, whereas radical removal of the bladder (RC—radical cystectomy) is implemented in those with MIBCa. To prevent recurrence and progression, TURBT is supplemented with intravesical instillations in select patients. Despite a number of surgical and anesthesiological improvements and wide adoption of perioperative chemotherapy, the long-term survival rates of patients with UBC have remained unchanged for decades. At the same time, our understanding of the disease biology by advanced molecular research has increased substantially. It is believed that therapy will be individualized and together with several refinements of surgical techniques and novel systemic as well intravesical treatment modalities will lead to better oncological outcomes of our patients. In this review, selected challenges and imminent perspectives with respect to bladder cancer epidemiology and management are presented and discussed. 2. EVIDENCE ACQUISITION A nonsystematic review of the PubMed database to identify articles focused on current challenges and future directions published in recent years in the English language was conducted. The following phrases were used during the search: urothelial cancer or bladder cancer, combined with several groups of keywords relevant to the discussed sections. These included: biology, etiology, epidemiology, management, and outcomes. Clinical series, review articles and editorials were identified, and all abstracts were reviewed but only the most significant papers were completely analyzed and used as references. 3. EVIDENCE SYNTHESIS 3.1. Epidemiology According to WHO reports, the incidence of BCa varies significantly among different geographical regions, such that age-standardized rates are almost three times greater in more developed areas than in less prosperous countries (9.5 vs. 3.3). The variety is among others suggested to result from disparities in tobacco smoking, obesity, alcohol consumption and overuse of red meat. Although the BCa risk is multifactorial, cigarette smoking remains the most prevalent risk factor. It has been estimated to be responsible for half of all BCa cases [5], with the magnitude of harms corresponding to smoking intensity and duration [6]. According to recent analysis, strong correlations between tobacco use and BCa incidence as well as mortality exist, though these are observed in males to a greater extent than females in both measures [3]. The WHO has issued a warning concerning the high prevalence of cigarette smoking and beforementioned risk factors across the European countries and at the same time provided number of pivotal interventions that policy-makers should implement to reduce the exposure [7]. Among many, the most important include the improvement of population awareness by comprehensive education campaigns, smoking ban in public places, increasing the price of cigarettes and alcohol, enhancing supermarket visibility of fruits and vegetables as well as their consumption, promoting physical activity by different measures such as stairs instead of lifts in attractive buildings and stimulating cycling as the most convenient means of transportation, restricting food advertising in media directed at children, banning industrially produced trans fatty acids and increasing duty on petrol [7]. Although on a global scale, rates of tobacco use are declining, the target of a 30% reduction by 2025 set by the WHO Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013–2020 is likely not to be achieved in the majority of countries. In the meantime, decreasing the prevalence of cigarette smoking in European countries is finally followed by a slow reduction in BCa-specific mortality [8]. The decline, however, does not result solely from the decrease in smoking pervasiveness but also from easier and quicker access to high-quality medical care, leading to early detection of potentially deadly disease. Analysis of the incidence of BCa throughout recent years in high-income countries has shown increasing tendencies with a corresponding decline in BCa-specific mortality [3]. There is no widely accepted BCa screening program. This is probably due to the low incidence of aggressive disease and lack of an optimal screening tool. Screening has been suggested, however, to be efficacious in highly selected populations. Those known to have aristolochic acid nephropathy were subjected to biannual cystoscopies for 10 years, and in half of them, BCa was diagnosed. After a median of 94 months follow-up, nobody died of the disease [9]. Therefore, the identification of vulnerable subpopulations that should be embraced by the appropriate screening program is crucial. Occupational exposures have long been associated with bladder cancer risk. While professions at the greatest risk include industrial areas processing paint, rubber, petroleum products and dye workers, the greatest risk of BCa specific mortality is observed in electrical and chemical process workers [10,11]. Of all BCa cases, no more than 8% are found to be attributable to such exposures [12]. However, some workers may be notably more prone to dismal effects of these subjections. Recent genetic study has revealed two carcinogen-detoxification genes NAT2 and GSTM1 that when abnormal lead to longer exposure to carcinogens [13]. As such, translational studies combining genetic